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Introduction
The accurate interpretation of biochemical and hematological 
blood analyses are an important aspect of clinical trials of pre-
ventive vaccines, both for trial inclusion decisions and post-inter-
vention safety evaluation. Reference intervals (RIs) are typically 
derived from historical literature values, laboratory instrument 
manufacturers or appropriate statistical analysis of routine clini-
cal laboratory patient data, all of which can introduce sampling 
bias.1,2 Blood results are affected by individual and laboratory 
factors, such as differences in age, gender, ethnicity, laboratory 
methods and laboratory instruments.3-5 While the gold stan-
dard is to minimize laboratory and population differences by 
computing institutional RIs, there are inherent problems with 
obtaining a sufficient sample size for such analyses, so validation 
of externally obtained RIs is recommended.6 In clinical trials of 
preventive vaccines, abnormalities in blood results from healthy 
young adults are usually defined by comparison with all age insti-
tutional or published RIs.7-10 There is a need to validate the RIs 
used in clinical trials to ensure they are applicable to the trial 
population. The data set of blood results from vaccine clinical 
trial programmes in healthy young adults at the Jenner Institute, 
Oxford, UK, is sufficiently large for calculation of the central 
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95% ranges for comparison with the institutional RIs. One of the 
interventions, MVA85A, a candidate tuberculosis vaccine, has 
been administered to over 100 healthy adults in a series of early 
clinical trials.11 Retrospective analyses of blood results obtained 
from asymptomatic adult subjects at the Jenner Institute and sub-
jects vaccinated with MVA85A were conducted and the litera-
ture reviewed in order to identify and account for discrepancies 
between the study population and the institutional RI. The main 
aim of these analyses was to develop recommendations for the 
interpretation of blood results obtained from healthy adult clini-
cal trial participants in Oxford, UK.
Results
Clinical trials, subjects and sample results. Between 1999 and 
2009, 38 clinical trials of candidate malaria, tuberculosis, influ-
enza and hepatitis C vaccines in healthy adult subjects were con-
ducted (unpublished trial by Porter et al., NCT00548444).12-37 
In total, 1106 screening appointments were attended by 974 
subjects, of which 70% were enrolled in a clinical trial (Fig. 1). 
Subjects aged 18 to 60 y were screened for inclusion in clinical 
trials, with a median female age of 25.3 y (IQR 9.1). The median 
age of male subjects was 26.3 y (IQR 9.7). Ethnicity data was not 
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institutional RI were determined, and 
the calculated 95% ranges for each 
analyte were compared with the insti-
tutional RI (Table 1). ALT and potas-
sium results were examined in further 
detail.
The calculated 95% range for ALT 
in female subjects was the same as the 
institutional RI. For male subjects, 
there were differences in ALT results 
between age tertiles (Kruskal-Wallis 
p = 0.0001) and a trend of increasing 
ALT result with increasing age (non-
parametric trend p = 0.001) (Fig. 2). 
Since there were fewer than 120 data 
points within each age tertile, 95% 
ranges of ALT results for two age quan-
tiles were calculated. For males aged 
18 to 24 y, the calculated 95% ranges 
were similar to the institutional RI. For 
males aged 25 to 35 y, 12% of results 
were above the upper limit and the 
calculated upper limit was more than 
1.5 times greater than the institutional 
upper limit for ALT. Repeat samples 
were available in 29 of the 37 (78%) 
subjects 18 to 40 y with an elevated 
ALT. Of these subjects, 11 (38%) had 
repeat samples within the institutional 
RI limits; 14 (48%) subjects’ repeat-
ing ALT results were mildly abnormal 
(up to twice the upper limit); and four 
(14%) subjects’ repeating ALT results 
were moderately abnormal (more than 
twice the upper limit).
One quarter of all potassium results were below the lower 
limit for the institutional RI and the calculated upper and lower 
limits were lower than those for the institutional RI. Median 
monthly potassium was lower in the summer than the winter 
months (Fig. 3A) and correlated negatively with mean maximum 
monthly temperature (Spearman rho = −0.76, p < 0.001). The 
frequency of below range potassium results was highest in the 
summer months (Fig. 3B).
Within-person variation. Analytes showing the greatest 
within-person variability were bilirubin, ALT, white cells and 
urea (Table 2). The most stable analytes with least within-per-
son variability were sodium, MCV, hemoglobin and albumin. 
Trends in within-person variation were comparable to previously 
published figures from large data sets. Pre-and post-interven-
tion results for 94 subjects who participated in clinical trials of 
a candidate tuberculosis vaccine, MVA85A, were also analyzed 
(Table 2). The median age of female subjects was 26.8 y (IQR 
9.2) and male subjects’ median age was 26.5 y (IQR 11.9). The 
median interval between pre-intervention screening samples and 
vaccination with MVA85A was 28 d (IQR 44). The median inter-
val between vaccination and post-intervention samples was 7 d 
routinely collected for all trials, but in a subset of 115 subjects 
participating in TB vaccine clinical trials, 80–100% of subjects 
were born in Europe.12,13,19,28
Between-person variation. The number of subjects aged 40 y 
and under who were included in the between-person analyses was 
818, of which 410 (50.1%) were male (Fig. 1). Female subjects’ 
median age was 24.7 y (IQR 6.6), and the median age of males 
analyzed was 25.1 y (IQR 6.7).
Fewer than 20 datapoints from samples run on the Bayer 
Axon were within each analyte and gender subgroup, which was 
insufficient for between-instrument comparisons. Samples run 
on the Bayer Axon were therefore excluded from further analysis. 
No clinically relevant differences in results between the Abbott 
Aeroset and Siemens ADVIA 2400 were identified and results by 
these two different instruments were combined for subsequent 
analyses (data not shown).
For all analytes, except alanine aminotransferase (ALT) in 
males, there were no differences in results between age tertiles 
using Kruskal-Wallis (data not shown). Results for subjects aged 
40 y and under were combined for subsequent analyses, except 
for ALT results in males. The proportions of results outside the 
Figure 1. sample selection for analysis. The flow of subject data which was included in each of the four 
analyses is shown. Where the same subject participated in more than one clinical trial, only the results 
from the first screening attendance were included in the between-person analyses.
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lower limit of the institutional RI. Hemoglobin and MCV were 
transiently reduced one week post-intervention. Hemoglobin fell 
below the lower limit of the institutional RI one week post-inter-
vention in five (6%) of subjects, all of whom were female, but in all 
cases returned to normal by 12 weeks post-intervention.
Proposed criteria for interpreting blood results in clini-
cal trials. Background evidence from published literature or 
(IQR 0). One post-intervention sodium result (109 mmol/L) for 
one subject was excluded from the analysis. This result was deemed 
aberrant as there were no associated symptoms of hyponatraemia 
and sodium was within the normal range (139 mmol/L) on a sam-
ple taken 2 d later. The repeat sodium result of 139 mmol/L was 
included. Albumin and bilirubin results were lower post-interven-
tion compared with pre-intervention but no results fell below the 
Table 1. study population blood results and the standard laboratory reference intervals (RI)
Analyte N Median result 
(IQR)
Institutional 
RI
Number of results outside 
institutional RI
Calculated 95% range following exclusion 
of outliers
Low (%) High (%) 2.5 97.5
albumin g/L
females 379 45 (4) 35–50 0 15 (4.0) 40 51
males 375 47 (4) 35–50 1 (0.3) 37 (9.9) 41 52
aLP IU/L
females 370 129 (47) 75–250 7 (1.9) 3 (0.8) 78 216
males 374 159 (50) 95–280 6 (1.6) 2 (0.5) 99 266
aLT IU/L
females 295 16 (8) 10–45 9 (3.0) 9 (3.0) 10 45
males (18–24 y) 135 19 (10) 10–45 3 (2.2) 4 (3.0) 11 46
males (25–35 y) 135 24 (15) 10–45 3 (2.2) 12 (12.6) 12 71
Bilirubin µmol/L
females 377 9 (4) 3.0–17.0 4 (1.0) 19 (5.0) 5 18.0
males 374 12 (6) 3.0–17.0 1 (0.3) 58 (15.5) 6 24.5
creatinine µmol/L
females 380 80 (13) 70–150 49 (12.9) 0 63 101
males 374 93 (14) 70–150 6 (1.6) 0 74 115
Potassium mmol/L
females 378 3.6 (0.5) 3.5–5.0 98 (25.9) 6 (1.6) 3 4.3
males 376 3.7 (0.4) 3.5–5.0 90 (23.9) 3 (0.8) 3.2 4.3
sodium mmol/L
females 380 139 (2) 135–145 2 (0.5) 2 (0.5) 136 142
males 376 140 (2) 135–145 0 4 (1.1) 137 144
Urea mmol/L
females 346 4.1 (1.2) 2.5–6.7 9 (2.6) 6 (1.7) 2.4 5.8
males 354 4.9 (1.4) 2.5–6.7 2 (0.6) 22 (6.2) 3.2 7
hemoglobin g/dL
females 373 13.2 (1.2) 12.0–15.0 29 (7.8) 10 (2.7) 11.5 14.8
males 377 15 (1.3) 13.0–17.0 7 (1.9) 5 (1.3) 13.2 16.5
McV fL
females 373 89.9 (9.9) 83–105 24 (6.4) 1 (0.3) 81.7 97.6
males 377 88.5 (5.2) 83–105 21 (5.6) 0 81.2 97.1
Platelets ×109/L
females 373 261 (79) 150–400 3 (0.8) 7 (1.9) 173 375
males 377 229 (58) 150–400 18 (4.8) 2 (0.5) 154 359
White cells ×109/L
females 373 6.2 (2.2) 4.0–11.0 24 (6.4) 10 (2.7) 3.8 10.7
males 377 5.7 (2.0) 4.0–11.0 34 (9.0) 5 (1.3) 3.6 10.2
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analysis accounted for the downward shift potassium levels com-
pared with the institutional RIs. Centrifuges have been installed 
in primary care practices, on the basis that correct results can 
only be ensured by centrifugation of samples in gel separator 
tubes.53 In Scotland, source centrifugation of samples taken in 
primary care facilities successfully reduced the frequency of pseu-
dohyperkalaemia.54 We propose a prospective study to investigate 
the effect of centrifugation at source on potassium results.
Discrepancies between the study population and the insti-
tutional RIs were further evaluated by using a well-recognized 
method for defining RIs, which is the basis for current guide-
lines.2,6,55,56 The central 95% of results for each analyte, sub-
grouped by gender, were calculated following removal of outliers. 
This method aims to maximise sensitivity and specificity by 
obtaining information from the extremes of the sample, while 
avoiding outliers adversely influencing the analysis. The impor-
tance of the calculated 95% ranges is that there is a danger that 
a clinically significant result which falls outside the calculated 
range for this healthy adult population, but within the limits of 
the institutional RI for all adults, may be clinically significant, 
but would be overlooked if referring only to the institutional RIs.
The calculated 95% range for ALT in males aged 25 to 40 y 
was higher than the institutional RI, reflecting increased levels 
in this subgroup, but adherence to the institutional RI for ALT 
is essential. Minimally elevated ALT levels are of clinical signifi-
cance (Table 3) and a number of groups have advocated reducing 
current upper normal limits.4,57 Current recommendations are for 
investigation of persistently elevated ALT of any degree above 
standard upper limits in asymptomatic individuals.58 We have, 
guidelines from recognized sources for each analyte, with rele-
vance for young, asymptomatic adult subjects, are summarized in 
Table 3. Cautionary ranges and expected variation from baseline 
are shown in Table 4.
Discussion
The validity of the institutional RIs for the young adult study 
population was first evaluated by determining the proportion of 
results which were outside the range of the institutional RI. The 
institutional RIs were two sided, defining the upper and lower 
limits of 95% of results. No analyte had both 2.5% of results 
above the upper limits and 2.5% of results below the lower limits, 
as would be expected. For analytes such as albumin and ALP, this 
may reflect differences between the all adult reference popula-
tions, often patients, from which institutional RIs were derived 
and the population of young, asymptomatic adults volunteering 
to participate in vaccine clinical trials at the Jenner Institute, 
Oxford (Table 3).
One in four potassium results in the study were below the 
lower limit of the institutional RI for potassium. Potassium levels 
in ex-vivo blood samples are not stable when stored prior to anal-
ysis unless centrifuged at the point of care.52 Seasonal pseudohy-
pokalaemia has been described and is hypothesized to be caused 
by ex-vivo sodium-potassium ATPase-mediated increased uptake 
of potassium by metabolically active cells in warm conditions.48,53 
We speculate that pseudhohypokalaemia due to storage of the 
samples at environmental temperature (centrally heated building 
in winter; no air conditioning in summer) prior to transport for 
Figure 2. aLT results for females aged 18 to 40 y; males aged 18 to 24 y and males aged 25 to 35 y are shown in a box plot. Boxes contain median lines 
and whiskers show the interquartile ranges. Dots are individual outliers.
©
20
13
 L
an
de
s 
B
io
sc
ie
nc
e.
 D
o 
no
t d
is
tri
bu
te
.
www.landesbioscience.com human Vaccines & Immunotherapeutics 1745
Figure 3. Potassium and environmental temperature. (A) Median monthly potassium and mean monthly maximum temperature. Median potassium 
results for each month are shown as connected points, with capped bars indicating the interquartile ranges. The line represents the mean monthly 
maximum temperature in Oxford, UK, from 1979–2000. The nadir median monthly potassium results corresponded with the summer months and 
the peak environmental temperature. a negative association between monthly median potassium and mean temperature was found (spearman rho 
= −0.76, p < 0.001). (B) Proportion of results indicating hypokalaemia and mean monthly temperature. The vertical bars indicate the percentage of 
samples with potassium results below the lower limit of the RI (3.5 mmol/L) each month. The line connects the mean maximum temperature for each 
month. Low potassium results were more frequent in the summer months than the winter months.
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95% range calculations.6 Data used for between-person analyses 
were taken pre-intervention, i.e., subjects were maintaining their 
usual lifestyle. Most specimens were taken in the mornings with 
subjects at rest thereby removing diurnal variation and exertion 
induced changes as confounding pre-analytical factors. Paired 
samples for the same individuals were available and all samples 
were processed in the same laboratory.
Limitations were that the study was retrospective and single 
centered. Various environmental factors were not controlled. 
Recreational drug use was an exclusion criterion, but subjects 
taking certain prescription drugs (such as the oral contraceptive 
pill) or over-the-counter remedies (e.g., for coryzal and musculo-
skeletal symptoms) were not excluded. Subjects were not required 
to fast overnight prior to phlebotomy and recent exercise may 
have been taken. After phlebotomy, times to sample analysis 
were not controlled. At the point of laboratory analysis, samples 
were not frozen, so between-run variation could not be elimi-
nated and replicate analyses of specimens were not performed. 
The trends in within-person variability were comparable to 
those previously published; suggesting factors which may have 
affected results remained consistent between sequential samples 
for individual subjects. Follow-up data were not available for sub-
jects with significantly or persistently abnormal results who were 
excluded from participation and referred for primary care follow 
up. Ethnicity and socio-economic data, anthropometric mea-
surements, iron studies in females and detailed smoking, alcohol, 
recent diet, exercise and menstrual history would strengthen the 
study.61,62
Taking the results of the analyses and the limitations of the 
study into consideration, recommendations for the interpreta-
tion of blood results in healthy adult subjects have been proposed 
(Table 4). Clearly, the calculated 95% ranges and coefficients 
of within-person variation are only valid for young, asymp-
tomatic adults whose blood samples are analyzed at the Oxford 
University Hospitals NHS Trust laboratories, UK. However, the 
methods described are straightforward and could be applied to 
other data sets from healthy adult subjects. Key components of 
therefore, proposed a clinical algorithm for the management of 
elevated ALT results in clinical trial populations (Fig. 4).
Understanding the expected degree of within-person varia-
tion for an analyte and the factors associated with variations 
is of particular importance for the interpretation of sequential 
results. Consistent with previous published data, bilirubin and 
ALT showed the greatest within-person variation. Transient fluc-
tuations are common and may be caused by recent alcohol con-
sumption, viral illnesses, concomitant medications and exercise 
patterns.59 For these analytes, transient fluctuations need to be 
distinguished from persistent elevations, by repeat testing and 
possible causes of transient fluctuations documented, by relevant 
history taking. It is intuitive to expect that analytes which vary 
greatly are likely to be the most frequently reported as abnormal 
in post-vaccination safety evaluation. For example, in a recent 
study of two candidate tuberculosis vaccines, MVA85A and 
FP85A, post-MVA85A vaccination ALT was elevated in one sub-
ject.12 The paired analysis of 94 pre- and post-MVA85A vaccina-
tion blood results, was reassuring in showing no frequent effect 
of MVA85A vaccination on ALT results.
The paired pre- and post-intervention analysis identified a 
transient reduction in hemoglobin and MCV in females, coin-
ciding with the time in the trials when the greatest blood vol-
umes were drawn. When the outcome measures of a clinical trial 
include the evaluation of vaccination induced immune responses, 
sizable blood samples (60–80 ml) are required from each partici-
pant at regular intervals. For trials such as these, we recommend 
adherence to national transfusion guidelines for the selection of 
blood donors, when setting trial inclusion criteria. In the UK, 
the minimum Hemoglobin levels for blood donors are 12.5 and 
13.5 g/dl females and males, respectively.60
The strengths of this study include the use of healthy young 
adult subjects, all of whom had a medical assessment. Subjects 
with pre-existing medical problems, alcohol excess or infection 
with blood borne viruses were excluded from the analysis. There 
were over 300 subjects per group, which was above the minimum 
recommended subgroup size (120 subjects) for non-parametric 
Table 2. Within-person variation and comparison of results pre-and post-MVa85a vaccination
Analyte N Males 
(%)
CVwpa for study 
population
Published 
CVwp38
Pre-intervention 
results median (IQR)
Post-intervention 
results median (IQR)
Median difference 
(IQR)
p valueb
albumin 476 229 (48) 5.0% 3.1% 46 (4) 45 (4) 1 (4) < 0.001
aLP 470 228 (49) 11.0% 6.4% 138 (57) 139 (60) 3 (21) 0.45
aLT 339 160 (47) 23.8% 18.0% 20 (10) 18 (10) 1 (8) 0.70
Bilirubin 479 231 (48) 28.4% 23.8% 10 (4) 10 (6) 1 (5) 0.01
creatinine 481 231 (48) 7.8% 6.0% 88 (16) 88 (22) 0 (10) 0.47
Potassium 481 230 (48) 9.1% 4.8% 3.7 (0.5) 3.7 (0.3) 0 (0.4) 0.75
sodium 449 231 (50) 1.3% 0.7% 139 (2) 139 (2.5) 0 (3) 0.44
Urea 339 223 (48) 16.2% 12.3% 4.3 (1.2) 4.4 (1.4) −0.1 (1.2) 0.39
hemoglobin 483 234 (48) 4.1% 2.8% 14.2 (2.3) 13.8 (2.2) 0.4 (0.8) < 0.001
McV 483 234 (48) 2.3% 1.3% 89.1 (5.4) 89.2 (5.4) 0.3 (2.2) 0.01
Platelets 483 234 (48) 10.0% 9.1% 260 (81) 256 (85) –4 (38) 0.09
White cells 483 234 (48) 19.6% 10.9% 5.9 (2.2) 5.7 (2.1) 0.1 (−1.6) 0.18
acVwp, within person coefficient of variation; bWilcoxon signed Rank paired analysis.
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exclude undisclosed medical conditions. Data from paper case 
report forms were entered onto an electronic database (Microsoft 
Excel). Accuracy of electronic data entry was verified by double 
data entry and crosschecking against paper records.
Laboratory results data set. Non-fasting phlebotomy was 
performed at the Centre for Clinical Vaccinology and Tropical 
Medicine, Oxford, during clinical trial clinics (07:30–11:00 
a.m.). Biochemistry samples were taken in lithium heparin 
and hematology samples in potassium EDTA (EDTA) using 
the Beckton Dickinson (BD) vacutainer collection system. 
Laboratory specimens were collected within two hours of phle-
botomy and transported two miles to the Oxford University 
Hospital NHS Trust Laboratories for same day analysis. Each 
blood tube was labeled with a unique study-specific identifica-
tion (ID) number and laboratory reports were generated for these 
study IDs. Trial and subject-specific ID numbers were used to 
retrieve laboratory results electronically.
All methods and instrumentation used were commonly used 
standardised methods. Albumin (bromocresol green method), 
alkaline phosphatase (ALP, DEA buffered enzymatic), alanine 
aminotransferase (ALT, enzymatic method), bilirubin (vana-
date oxidation method), creatinine (Jaffe method), sodium 
and potassium (both ion selective electrode methods) and urea 
(urease method) were undertaken on three different clinical 
chemistry analysers over the period studied. Samples analyzed 
before February 2000 utilized the Bayer Axon analyzer (Bayer 
Diagnostics); samples from March 2000 and March 2006 were 
analyzed on an Abbott Aeroset (Abbott diagnostics); and samples 
the clinical assessment conducting during clinical trial screening, 
pertinent to the interpretation of blood results, include ethnic 
origin; detailed alcohol, smoking, diet, exercise and medica-
tion history; recent mild illness; history of significant acute or 
chronic disease; height, weight and blood pressure measurements 
and urinalysis for blood, protein and glucose. When taking post-
intervention blood tests for safety evaluation, concurrent history 
of recent symptoms, diet, exercise, medication and alcohol intake 
are recommended.
There is a recognized need to standardise safety reporting 
across clinical trials of vaccines and the Brighton Collaboration, a 
global research network, is developing case definitions and guide-
lines to this end.63 This study provides important data on which 
to base further work to validate RIs for young, asymptomatic 
adults to enable the accurate interpretation of blood results in 
clinical trials.
Materials and Methods
Subject data set. A retrospective analysis of screening atten-
dances, screening outcomes and laboratory results included 
all clinical trials recruiting healthy adult subjects at the Jenner 
Institute, Oxford, UK, between 1999 and 2009. Trials were 
conducted in accordance with the Declaration of Helsinki 
and ethical approval obtained. Informed consent was obtained 
before conducting any study procedures. Subjects were assessed 
by medical history, physical examination, laboratory assessment 
and corroborative medical history from General Practitioners, to 
Table 3. summary of available literature
Analyte Considerations for young, asymptomatic adults
albumin albumin levels decrease with age.39 Young, healthy adults are likely to have higher albumin levels due to good nutritional status and 
liver synthetic capacity.
aLP aLP levels are stable in young adults, following cessation of growth and bone turnover and increase in the fourth decade.2,40
aLT BMI has the strongest independent association with aLT in healthy populations, but increased aLT levels are also associated with male 
gender age, peaking at 55 y of age.4,41,42 Non-alcoholic fatty liver disease (NaFLD) is an important cause of persistently elevated aLT lev-
els in asymptomatic adults and is estimated to have a prevalence of 20–30% in countries such as the UK.43 aLT levels at the upper end 
of the normal range are associated with an increased mortality from liver disease.44
Bilirubin The most likely cause of persistently elevated bilirubin in asymptomatic individuals with normal unconjugated bilirubin levels and oth-
erwise normal liver function tests is Gilbert’s syndrome, which has a prevalence of 5–10%.45
creatinine creatinine production is determined by muscle mass and dietary intake and is affected by gender and ethnicity, with high inter-person 
variability, so a single RI is not entirely appropriate for a population.46 estimates of Glomerular Filtration Rate (eGFR) may take age, gen-
der, ethnicity and body mass into account, but have usually been developed for patients with chronic kidney disease and may not be 
applicable to an asymptomatic population.46,47
Potassium Potassium has a widely used reference range of 3.5–5.0 mmol/L.9,10 ambient temperature is an important cause of spurious hypo- and 
hyperkalaemia when samples are stored prior to analysis.48,49
sodium sodium has a narrow homeostatic range and shows very little inter-person variation.3 exercise-associated hyponatraemia occurs after 
excessive exercise, such as marathons.
Urea Between-person urea levels are highly variable and are related to protein intake, being higher in males than females and increase with 
age.50 Within-person variations are associated with dehydration, alcohol intake and concomitant medication.
hemoglobin hemoglobin RIs are consistently lower in females than males.9,10
McV causes of raised McV include excessive alcohol intake and macrocytic anemia. Iron deficiency and thalassaemia should be considered 
for low McV values.
Platelets Platelet counts are lower in african and afro-caribbeans than caucasians.5 The most widely used lower limit is 150 × 109/L.51 Blood 
smear to exclude pseudothrombocytopenia is indicated for results below the lower limit.51
White cells White cell counts are lower in african and afro-caribbeans than caucasians and are higher in women than men.5
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illicit drug use; excessive alcohol intake or if infection with a 
blood borne virus was detected at screening.
Statistical analysis. Data were analyzed using Stata (Stata 
statistical software version 9.0, 2005, StataCorp, USA). Data 
were first visually reviewed to check for heavy skewing by indi-
vidual results, using histograms and box plots. Continuous vari-
ables were not normally distributed and were summarized using 
median and interquartile range (IQR).
For between-person analyses, results for each analyte were 
filtered to include one pre-intervention result per subject and 
were sub-grouped by gender. Differences in the distribution 
of data between instrument subgroups were compared using 
Kolmogorov-Smirnov, before combining the data derived from 
different instruments. Subjects over 40 y of age were excluded 
and subjects 40 y and under were partitioned into age tertiles. 
Differences between age tertiles were evaluated by Kruskal-
Wallis. Where differences were detected, a non-parametric test 
for trend across ordered groups was performed. Where no dif-
ferences between age tertiles were detected, 95% ranges for 
combined data from subjects of all ages 40 y and under were 
calculated.
The 95% range for each analyte was calculated using a stan-
dard method.2,6,55,56 Normality of data within each subgroup was 
assessed graphically by normal probability plots (for evaluating 
central normality) and normal quantile plots (for identifying 
deviations from normality at the tails of the data). The Shapiro–
Wilk test for skewness and kurtosis and the Kolmogorov-
Smirnov test against an empirical normal distribution were 
performed. Where data were not normally distributed, Box–Cox 
transformations within each group or subgroup were performed. 
The effect of normalizing transformation was assessed graphi-
cally and statistically as above. The upper (Q1) and lower (Q3) 
quartiles and IQR (Q1–Q3) of the transformed data were cal-
culated. Data points lying outside the range (Q1–1.5 × IQR) to 
(Q3 + 1.5 × IQR) were identified as outliers and excluded.2 Non-
parametric 95% ranges were derived by obtaining the 2.5th and 
97.5th percentiles of the raw data after exclusion of outliers. 
Parametric 95% ranges were derived by calculating mean ± 1.96 
× standard deviations (SDs) of the raw data after exclusion of 
outliers.
The analysis of within-person variation included all clinical 
trial participants 40 y and under for whom at least two sequen-
tial results per analyte were available. If a subject had partici-
pated in more than one clinical trial, samples were taken from 
the first clinical trial in which they had participated. The first 
(r1) and last (r2) retrieved results for each subject were included 
in the analysis. This minimised any effect of intervention on 
the analysis, since the first samples for each subject were pre-
intervention and the last samples were taken at least 12 weeks 
post-intervention. The within-person coefficient of variation 
was calculated using a described method.62 The square of the 
coefficient of variation (CV2) for each subject was calculated 
by [(within subject variance)/(mean)2], where within subject 
variance was [(r1−r2)2/2] and mean result was [(r1+r2)/2]. 
The within-person coefficient of variation for the sample was 
obtained by calculating the root mean square; {[√(mean 
obtained from April 2006 to December 2009 were analyzed on 
a Siemens ADVIA 2400 (Siemens Diagnostics). RIs remained 
consistent despite these two changes of instrument as no clini-
cally significant shifts in results were detected by comparison 
studies (T. James, personal correspondence). Haematological 
parameters were analyzed on the Sysmex XE-2100 hematology 
analyzer. The longitudinal stability of all assays was controlled 
through internal quality control and external quality assurance 
participation.
Laboratory data were excluded pre-analysis if medical assess-
ment had revealed significant past medical or psychiatric history; 
Table 4. Recommendations
Analyte Institutional 
RI
Cautionary 
rangea
Expected variation 
from baselineb
albumin g/L 5%
females 35–50 35–39 2–3
males 35–50 35–40 2–3
aLP IU/L 11%
females 75–250 217–250 8–28
males 95–280 267–280 10–31
aLT IU/L 24%
females and males 10–45 2–11
Bilirubin µmol/L 28%
females and males 3.0–17.0 1–5
creatinine µmol/L 8%
females 70–150 102–150 6–12
males 70–150 116–150 6–12
Potassium mmol/L 9%
females and males 3.5–5.0 4.4–5.0 ≤ 0.5
sodium mmol/L 1%
females and males 135–145 1–2
Urea mmol/L 16%
females 2.5–6.7 5.8–6.7 ≤ 1
males 2.5–6.7 ≤ 1
hemoglobin g/dl 4%
females 12.0–15.0 < 1
males 13.0–17.0 < 1
McV fL 2%
females and males 83–105 98–105 2
Platelets ×109/L 10%
females 150–400 150–172, 
376–400
15–40
males 150–400 360–400 15–40
White cells ×109/L 20%
females 4.0–11.0 1–2
males 4.0–11.0 1–2
aThe cautionary ranges were based upon discrepancies between the 
institutional RIs and the calculated 95% ranges. bThe expected variations 
from baseline were based upon the calculated within person coefficents 
of variation.
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CV2)]*100}. The standard error was calculated by 
[(standard deviation of CV2s)/(√sample size)].
The seasonality of potassium results were evalu-
ated by comparing median monthly potassium results 
against average monthly temperatures. Potassium 
results from subjects aged 40 y or under were ana-
lyzed. Data were grouped by the month the sample was 
obtained. Monthly average temperatures in Oxford 
over a 30-y period from 1971–2001 were obtained from 
the Meterological Office.64 The association between 
median monthly potassium and mean monthly tem-
perature was evaluated by Spearman’s rho correlation 
coefficient.
Paired pre- and post-intervention results were ana-
lyzed for the candidate tuberculosis vaccine MVA85A 
(ClinicalTrials.gov registration number of unpublished 
trial by Porter et al., NCT00548444).12,13,19,25,28,35 The 
latest pre-intervention and earliest post-intervention 
results available were included in the analysis. Results 
were excluded if samples were obtained greater than one 
month (31 d) post-intervention, since vaccine-related 
adverse events and cellular immune responses peak one 
to two weeks post-vaccination.21,29,35,65
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Figure 4. algorithm for management of elevated aLT in the clinical trial setting.
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